Axsome Therapeutics Inc - To Discuss the Topline Results of the ADVANCE-1 trial of AXS-05 in Alzheimer's Disease Agitation - Conference Call Transcript
Good morning, ladies and gentlemen, and welcome to Axsome Therapeutics' conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Mark Jacobson, Chief Operating Officer, Axsome Therapeutics. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining us on today's conference call to discuss the positive top line results from the ADVANCE-1 Phase II/III trial of AXS-05 in Alzheimer's disease agitation. A press release announcing that AXS-05 achieved the primary endpoint in the trial crossed the wire a short time ago and is available on our website at axsome.com.
During today's conference call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety and intended utilization of our investigational agents; our clinical and nonclinical plans; our plans to present or
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |